Table 1. . Summary of published experience with radioembolization in hepatocellular carcinoma (by disease stage) in comparison with conventional transarterial embolization and sorafenib.

Study (year)	Study design	Treatment	Child-Pugh class	Early		Intermediate		Advanced						Ref.
								Overall		Patent portal vein		Portal vein occlusion
				n	Median OS (95% CI) mo	n	Median OS (95% CI), months	n	Median OS (95% CI), months	n	Median OS (95% CI), months	n	Median OS (95% CI), months
Salem et al. (2011)	Retrospective case series	Conventional TACE	Overall A (n = 67) B (n = 53)	47	45.4 (15.1–46.1)	61	17.5 (14.8–18.7)	12	9.3 (6.2–11.5)	–	–	–	–	[34]
Hilgard et al. (2010)	Retrospective case series	Radioembolization	Overall	–	–	47	16.4 (12.1–NC)	51	NR	75	16.4 (12.1–NC)	33	10.0 (6.0–NC)	[35]
		TheraSphere	A (n = 84)	17.2 (12.1–NC)
			B (n = 24)				6.0 (4.2–NC)
Salem et al. (2010)	Prospective case series	Radioembolization	Overall	48	26.9 (17–30.2)	83	17.2 (13.5–29.6)	107	7.3 (6.5–10.1)†	–	NR	–	NR	[36]
		TheraSphere	A	27	20.5 (15–27.4)	48	17.3 (13.7–32.5)	41	13.8 (8.8–17.7)†	6	47.4 (NR)†	35	10.4 (7.2–16.6)†
			B	21	29.1 (17–NC)	35	13.5 (6.4–25.4)	66	6.4 (4.9–7.7)†	9	11.8 (NC–34)†	57	5.6 (4.5–6.7)†
Sangro et al. (2011)	Retrospective case series	Radioembolization	Overall	52	24.4 (18.6–38.1)	87	16.9 (12.8–22.8)	183	10.0 (7.7–10.0)	110	9.3 (7.4–11.4)	73	10.2 (7.7–11.8)	[37]
		SIR-Spheres	A	47	30.9 (18.6–45.9)	82	18.4 (13.6–23.2)	137	9.7 (7.6–10.9)
			B	5	19.4 (6.5–27.4)	5	3.6 (2.4–10.8)	46	10.0 (6.1–14.5)
Cheng et al. (2009)	Prospective RCT	Sorafenib	A	–	–	–	–	150	6.5 (5.6–7.6)	96	NR	54	NR	[38]
Llovet et al. (2008)	Prospective RCT	Sorafenib	Overall A (n = 284) B (n = 14)	–	–	54	14.5 (NR)	244	9.7 (NR)	191	NR	108	NR	[39,40]

^†Without extrahepatic disease.

NC: Not calculated; NR: Not reported; OS: Overall survival; RCT: Randomized controlled trial; TACE: Transarterial chemoembolization.